Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity

2003 • 1,338 citations

Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp

2005 • 502 citations

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

2004 • 413 citations

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

2005 • 315 citations

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

1997 • 314 citations

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

1999 • 286 citations

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

2003 • 282 citations

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

1998 • 207 citations

The ErbB receptor family: a therapeutic target for cancer

2002 • 204 citations

First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer

2001 • 185 citations

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

2000 • 179 citations

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells

2001 • 152 citations

Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.

1987 • 140 citations

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

2004 • 120 citations

Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor

2005 • 35 citations

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

2002 • 21 citations